GLP‑1 Drugs: More Than Weight Loss – A Look at Liver, Joints and Aging

GLP‑1 medicines have become popular worldwide for cutting weight and managing diabetes. New data show that their use has jumped sharply in the United States, especially among people who do not have diabetes. Researchers are now finding that these drugs may also help the liver, protect knees and even slow biological aging. In one study, scientists examined a special group of people who feel hungry for longer after eating – the so‑called “hungry gut” type. Those patients responded best to a drug that mimics two hormones, GLP‑1 and GIP. They lost more weight than other groups when treated with this medicine, suggesting that doctors could pick the right drug for each person instead of using a one‑size approach. Another trial at UC San Diego tested whether a GLP‑1 drug could heal scar tissue in the liver of people with serious fatty liver disease. The results showed a clear reduction in scarring after one year, even when the patients already had advanced disease. This could give a new treatment option for those who previously had very few choices.

Research on joint health used data from almost 115, 000 patients with knee osteoarthritis. Those who took newer GLP‑1 medicines for three years had a lower chance of needing knee replacement surgery after eight years. The findings hint that keeping the body metabolically healthy might protect joints for a long time. Finally, a study of adults with HIV looked at how a GLP‑1 drug affected DNA changes that signal aging. The medication slowed the progression of several biological clocks by about nine percent, indicating a potential benefit for extending healthy life span. These studies together paint a picture of GLP‑1 drugs as versatile tools that may improve liver function, joint health and aging, beyond their known role in weight control.

Actions